PDE4A and chronic obstructive pulmonary disease: Roflumilast is the first phosphodiesterase 4 (PDE4) inhibitor indicated for chronic obstructive pulmonary disease (COPD) in 2011, subsequently for plaque psoriasis approved by the U.S. Food and Drug Administration (FDA) and Health Canada [1, 2].